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Volume 40, Number 1 Jackson et al 23outcome in young patients with advanced atherosclerosis. I don’t
know why they had that; I can’t specifically answer that.
Dr James Seeger (Gainesville, Fla). If you look at your data
and the other reported data, about half of these patients benefit
from having an SFV ABF and half of them don’t, because only half
the Dacron grafts fail at 5 years. So do you have a way of picking
out the ones we ought to be doing this more extensive procedure
in, or alternatively picking out the ones, the young patients, who
will tolerate a standard procedure?
Dr Ali. I would say I don’t know the answer to that exactly,
but somebody who is less than 50 years old with small aortic size
and critical ischemia who is a good operative risk and not morbidly
obese, I think those are the patients who benefit from this, because
the secondary interventions on these vein grafts are almost nonex-
istent. There were five patients who had subsequent distal bypassesdone, but these patients lived their lives without intervention, and
the grafts not getting any stenosis or occlusion. I don’t know the
exact answer of how those patients. . .I think that is maybe C-re-
active protein or something.
Dr Thomas Huber (Gainesville, Fla). Given this high-risk
patient population, what is your first choice of operation? Do you
do a Dacron bypass or do you go to the SFV bypass first?
Dr Ali. We still do the Dacron bypass in a good-risk patient
who is 55 or older or has a good sized aorta that is 20 mm, or more
than a 19-mm diameter. Again, this is a highly selected group of
patients. We do go to an endovascular approach if that is feasible.
If not, then we do offer both the vein graft and the Dacron graft to
the patients. Surprisingly, the patients want their own tissue. They
insist on the vein graft even though it is associated with high
morbidity.CORRECTIONS
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